Cardiotoxicity of Multimodal Treatment for Breast Cancer


In the era of the optimal and the personalized oncological treatments, life expectancy increases, therewith the need of understanding and managing side effects is a challenging task.
The most notable research advances in breast cancer involve new radiation treatments techniques and targeted therapies.
Cardiac toxicity following radiotherapy (RT) is recognized as an important issue. Furthermore, with the prevalent and necessary treatment with anthracyclines and trastuzumab, which carry an independent and confirmed risk of cardiotoxicity[1-3] the additional heart disease risk following radiotherapy must be kept to a minimum. […]